American Century Companies Inc. Purchases New Shares in Compass Therapeutics, Inc. $CMPX

American Century Companies Inc. acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 73,682 shares of the company's stock, valued at approximately $140,000. American Century Companies Inc. owned 0.05% of Compass Therapeutics at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Nuveen LLC bought a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $579,000. Deutsche Bank AG bought a new stake in Compass Therapeutics in the 1st quarter valued at $194,000. Charles Schwab Investment Management Inc. increased its holdings in Compass Therapeutics by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company's stock valued at $566,000 after buying an additional 11,689 shares during the period. Bank of New York Mellon Corp increased its holdings in Compass Therapeutics by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock valued at $463,000 after buying an additional 5,590 shares during the period. Finally, Vontobel Holding Ltd. bought a new stake in Compass Therapeutics in the 1st quarter valued at $57,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX traded up $0.18 during midday trading on Thursday, reaching $3.70. 824,554 shares of the company traded hands, compared to its average volume of 1,371,542. The firm has a market cap of $511.64 million, a PE ratio of -8.22 and a beta of 1.50. The stock's 50-day simple moving average is $3.07 and its 200-day simple moving average is $2.49. Compass Therapeutics, Inc. has a 12 month low of $1.27 and a 12 month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

CMPX has been the topic of several analyst reports. Guggenheim boosted their price target on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. Finally, D. Boral Capital reissued a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics currently has an average rating of "Buy" and a consensus target price of $12.89.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.